前列腺癌原发局灶治疗技术如何选择:ESUT立场声明
欧洲泌尿技术学会(ESUT)专家小组基于文献与专家意见,综述高强度聚焦超声、冷冻治疗、局灶激光消融等技术在局灶治疗中的利弊。不同技术副作用低,尿控率90-100%,勃起功能障碍5-52%;专家共识认为后部病灶更适合HIFU,前部肿瘤冷冻治疗最佳,尖部病灶FBT尿道并发症最少。
要点
- 局灶治疗各技术尿控率90-100%,勃起功能障碍5-52%。
- 专家共识:后部病灶更适合HIFU,前部肿瘤冷冻治疗最佳。
- 尖部病灶采用FBT可能尿道并发症最少。
核心结论
- ESUT专家共识认为不同局灶治疗技术可能更适合不同肿瘤位置。
- 肿瘤风险、大小、位置和前列腺体积均是选择技术时需考虑的重要因素。
- 仍需前瞻性试验评估各消融技术的中长期疾病控制。
研究设计与样本
- ESUT专家小组基于文献综述与专家意见形成立场声明。
- 文献筛选因素包括发病率、可重复性、肿瘤风险类别、肿瘤位置、肿瘤大小、前列腺体积和解剖问题。
主要发现
- 不同研究及局灶治疗技术副作用均较低,尿控率90-100%,勃起功能障碍5-52%。
- 基于治疗后活检的短期至中期癌症控制在不同消融技术间存在差异。
- 专家共识提示后部病灶更适合HIFU,前部肿瘤冷冻治疗结果最佳。
- 尖部病灶采用FBT可能尿道并发症最少。
关键数值与推荐
- 尿控率90-100%,勃起功能障碍5-52%。
- 专家共识推荐后部病灶使用HIFU,前部肿瘤使用冷冻治疗,尖部病灶使用FBT。
临床怎么用
- 根据肿瘤位置选择局灶治疗技术:后部选HIFU,前部选冷冻治疗,尖部选FBT。
- 选择技术时需综合考虑肿瘤风险、大小、位置及前列腺体积。
局限性
- 基于文献和专家意见的共识,非系统评价或随机试验。
- 短期至中期癌症控制数据在不同消融技术间可变。
- 需进一步前瞻性试验评估中长期疾病控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With growing interest in focal therapy (FT) of prostate cancer (PCa) there is an increasing armamentarium of treatment modalities including high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation (FLA), irreversible electroporation (IRE), vascular targeted photodynamic therapy (VTP), focal brachytherapy (FBT) and stereotactic ablative radiotherapy (SABR). Currently there are no clear recommendations as to which of these technologies are appropriate for individual patient characteristics. Our intention was to review the literature for special aspects of the different technologies that might be of advantage depending on individual patient and tumour characteristics. METHODS: The current literature on FT was screened for the following factors: morbidity, repeatability, tumour risk category, tumour location, tumour size and prostate volume and anatomical issues. The ESUT expert panel arrived at consensus regarding a position statement on a structured pathway for available FT technologies based on a combination of the literature and expert opinion. RESULTS: Side effects were low across different studies and FT modalities with urinary continence rates of 90-100% and erectile dysfunction between 5 and 52%. Short to medium cancer control based on post-treatment biopsies were variable between ablative modalities. Expert consensus suggested that posterior lesions are better amenable to FT using HIFU. Cryotherapy provides best possible outcomes for anterior tumours. Apical lesions, when treated with FBT, may yield the least urethral morbidity. CONCLUSIONS: Further prospective trials are required to assess medium to long term disease control of different ablative modalities for FT. Amongst different available FT modalities our ESUT expert consensus suggests that some may be better for diffe`rent tumour locations. Tumour risk, tumour size, tumour location, and prostate volume are all important factors to consider and might aid in designing future FT trials.
引用
- Ganzer R, Arthanareeswaran VKA, Ahmed HU, et al. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement. Prostate Cancer Prostatic Dis. 2018. PMID: 29743538. doi:10.1038/s41391-018-0042-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。